| Austin Jordan Shinaberry, PHYSICIAN ASSISTANT | |
|
16 Grove St, Charleston, SC 29403-3706 | |
| (386) 383-6088 | |
| Not Available |
| Full Name | Austin Jordan Shinaberry |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 16 Grove St, Charleston, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053175661 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | (* (Not Available)) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Austin Jordan Shinaberry, PHYSICIAN ASSISTANT 16 Grove St, Charleston, SC 29403-3706 Ph: (386) 383-6087 | Austin Jordan Shinaberry, PHYSICIAN ASSISTANT 16 Grove St, Charleston, SC 29403-3706 Ph: (386) 383-6088 |
News Archive
The largest study of childhood eye diseases ever undertaken in the U.S. confirms that the incidence of childhood myopia among American children has more than doubled over the last 50 years. The findings echo a troubling trend among adults and children in Asia, where 90 percent or more of the population have been diagnosed with myopia, up from 10 to 20 percent 60 years ago.
Monitoring blood for tiny particles released by cells lining the lungs may help clinicians diagnose emphysema in its earliest stages, according to researchers from Weill Cornell Medical College. The particles, called endothelial microparticles, are shed during the disease process as tiny blood vessels in the lungs, called pulmonary capillaries, are injured and die.
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
Gold nanoshells are among the most promising new nanoscale therapeutics being developed to kill tumors, acting as antennas that turn light energy into heat that cooks cancer to death. Now, a multi-institutional research team has shown that polymer-coated gold nanorods one-up their spherical counterparts, with a single dose completely destroying all tumors in a nonhuman animal model of human cancer.
› Verified 6 days ago